Scott Kopetz, MD, PhD | Authors


Updated Survival Data from BEACON CRC Lead to More Specific Questions

June 02, 2020

Scott Kopetz, MD, PhD, discusses the next steps following the phase 3 BEACON CRC trial of encorafenib plus cetuximab with or without binimetinib compared with irinotecan or FOLFIRI plus cetuximab in patients with BRAF V600E metastatic colorectal cancer.